CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence
CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.
CBL-514 Dosages - what does science say?
CBL-514 trials are investigational injection protocols, and the "600 mg" figure is a per-treatment cap, not a supplement dose. This article walks through the Phase 2a dose-finding study (1.2, 1.6 and 2.0 mg/cm² over 150 cm², n=43, open-label) and explains where the much-quoted 24.96% figure comes from. It then covers the placebo-controlled Phase 2, which kept 2.0 mg/cm² but doubled the area to 300 cm² and raised the cap to 600 mg. You will see why mg totals cannot be compared across studies, what safety was reported, and why this is still not approved or advice.
Does CBL-514 really burn fat? Here's what we know
The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.
How does CBL-514 work? Here's the science
CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.
CBL-514 fat removal injections: What does the science say?
CBL-514 now has a placebo-controlled Phase 2 randomized trial in Aesthetic Surgery Journal, and the authors report it met its primary and secondary endpoints. But this appraisal shows why the design deserves a hard look: it was single-blind with unblinded investigators and sponsor, and the sponsor helped design, analyze and write the study. Of 75 treated participants, only 38 finished, and the per-protocol set was just 30 people. Follow-up ended 8 weeks after the final treatment, and the sample was mostly female and White. Here is what the trial can support, what it cannot, and why it is not medical advice or proof of an approved treatment.
What is CBL-514? Does it burn fat?
CBL-514 is being called a fat-dissolving shot, but it is not a fat burner, a supplement, or a GLP-1. It is an investigational small-molecule injection from Caliway Biopharmaceuticals, designed to trigger fat-cell apoptosis in the area where it is injected. In a 2025 Phase 2 trial, abdominal fat volume dropped versus placebo, with a mean difference of about −216 mL at 8 weeks. Mean body weight in the CBL-514 group was essentially unchanged (+0.02 kg), so this is local fat reduction, not systemic fat burning. High dropout, single-blind design, and sponsor involvement mean the results need cautious reading.